Capital Fund Management (CFM)
REGN icon

Capital Fund Management (CFM)’s Regeneron Pharmaceuticals REGN Stock Holding History

Capital Fund Management (CFM)’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,000
Closed -$11.6M – 2474
2025
Q4 		$11.6M Sell
15,000
-11,600
-44% -$7.88M 0.03% 742
2025
Q3 		$15M Sell
26,600
-5,100
-16% -$2.88M 0.04% 639
2025
Q2 		$16.6M Sell
31,700
-48,000
-60% -$26.8M 0.05% 523
2025
Q1 		$50.5M Buy
79,700
+44,600
+127% +$30.7M 0.15% 202
2024
Q4 		$25M Buy
+35,100
New +$29.5M 0.06% 405
2024
Q2 		– Sell
-17,600
Closed -$16.9M – 2122
2024
Q1 		$16.9M Buy
+17,600
New +$16.7M 0.05% 511
2022
Q2 		– Sell
-11,700
Closed -$8.17M – 1620
2022
Q1 		$8.17M Buy
+11,700
New +$7.4M 0.07% 396
2020
Q3 		– Sell
-14,900
Closed -$9.29M – 1358
2020
Q2 		$9.29M Sell
14,900
-2,900
-16% -$1.65M 0.15% 200
2020
Q1 		$8.69M Sell
17,800
-5,300
-23% -$2.19M 0.13% 204
2019
Q4 		$8.67M Sell
23,100
-13,700
-37% -$4.61M 0.07% 386
2019
Q3 		$10.2M Sell
36,800
-94,800
-72% -$28.1M 0.09% 292
2019
Q2 		$41.2M Buy
131,600
+124,800
+1,835% +$41.5M 0.37% 46
2019
Q1 		$2.79M Sell
6,800
-19,800
-74% -$8.15M 0.03% 683
2018
Q4 		$9.94M Sell
26,600
-34,200
-56% -$12.5M 0.09% 321
2018
Q3 		$24.6M Sell
60,800
-76,500
-56% -$29.1M 0.13% 204
2018
Q2 		$47.4M Buy
137,300
+28,700
+26% +$8.98M 0.25% 105
2018
Q1 		$37.4M Buy
108,600
+54,700
+101% +$19M 0.22% 115
2017
Q4 		$20.3M Sell
53,900
-48,100
-47% -$19.5M 0.11% 226
2017
Q3 		$45.6M Buy
102,000
+900
+0.9% +$428K 0.33% 71
2017
Q2 		$49.7M Buy
+101,100
New +$44.2M 0.4% 50
2017
Q1 		– Sell
-2,500
Closed -$918K – 1765
2016
Q4 		$918K Sell
2,500
-15,600
-86% -$5.93M 0.01% 1045
2016
Q3 		$7.28M Sell
18,100
-11,100
-38% -$4.45M 0.07% 346
2016
Q2 		$10.2M Buy
29,200
+25,300
+649% +$9.74M 0.1% 256
2016
Q1 		$1.41M Buy
3,900
+100
+3% +$41.2K 0.01% 791
2015
Q4 		$2.06M Sell
3,800
-500
-12% -$271K 0.02% 660
2015
Q3 		$2M Sell
4,300
-6,300
-59% -$3.38M 0.02% 620
2015
Q2 		$5.41M Buy
+10,600
New +$5.17M 0.07% 369
2015
Q1 		– Sell
-700
Closed -$287K – 1672
2014
Q4 		$287K Buy
+700
New +$275K ﹤0.01% 1364
2014
Q3 		– Sell
-2,500
Closed -$706K – 1772
2014
Q2 		$706K Sell
2,500
-1,600
-39% -$474K 0.01% 1088
2014
Q1 		$1.23M Buy
4,100
+2,400
+141% +$739K 0.02% 884
2013
Q4 		$468K Sell
1,700
-2,900
-63% -$834K 0.01% 1280
2013
Q3 		$1.44M Sell
4,600
-148,000
-97% -$38.9M 0.02% 743
2013
Q2 		$34.3M Buy
+152,600
New +$35.5M 0.52% 13

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital Fund Management (CFM)'s REGN Position: Q4 2025 in Review

Capital Fund Management (CFM) sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 58,834 shares — an estimated $40M sold.

Capital Fund Management (CFM) first reported a position in REGN in Q1 2014 and held it in 18 quarters. The position peaked at $58.9M in Q1 2025. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Capital Fund Management (CFM) reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 58,834 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $40M.
  • Capital Fund Management (CFM) first reported a position in Regeneron Pharmaceuticals in Q1 2014 and held it in 18 quarters.
  • Capital Fund Management (CFM)'s Regeneron Pharmaceuticals position peaked at $58.9M in Q1 2025.
  • 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q4 2025, filed 17 Feb 2026.